X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the manufacturing and clinical trials of potent inhibitor known as HM43239 (tuspetinib) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hanmi Pharmaceutical
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Details:
Aptose intends to use the net proceeds to support clinical trials for HM43239 (tuspetinib), a once daily oral therapy being studied as monotherapy and in combination therapy in Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 26, 2024
Details:
The proceeds will be used for Aptose’s lead hematology drug, tuspetinib, formerly HM43239, an orally active small molecule inhibitor of FLT3, currently in Phase 1/2 trial in which patients with R/R AML receive tuspetinib monotherapy or in combination with venetoclax.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hanmi Pharmaceutical
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 06, 2023
Details:
HM43239 (tuspetinib), once daily oral agent which inhibts SYK, JAK1/2, FLT3, and other kinases operative in AML, by inhibiting tyrosine kinase, tucatinib exerts anti-tumor activity, reducing the size of HER-2 positive breast cancer tumors.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
HM43239 (tuspetinib), a once daily oral agent designed to target FLT3, SYK, and JAK kinases but avoid targets that drive toxicities, safely delivered complete remissions as a monotherapy across four dose levels (40mg, 80mg, 120mg, and 160mg) in acute myeloid leukemia.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2022
Details:
HM43239 is a potent oral genotype-agnostic small molecule inhibitor of a constellation of kinases operative in myeloid malignancies and known to be involved in tumor proliferation, resistance to therapy, and differentiation.
Lead Product(s): Tuspetinib
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
CG-806 (luxeptinib) is an orally bioavailable kinase inhibitor with potency against select kinases including BTK, inhibits NLRP3 inflammasome function in THP-1 monocytes and bone marrow-derived macrophages.
Lead Product(s): Luxeptinib
Therapeutic Area: Oncology Product Name: CG-806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
APTO-253 remains an interesting product that has demonstrated MYC repression, which creates optionality across the wider oncology spectrum. Clinical development of the MYC repressor APTO-253 will be discontinued.
Lead Product(s): APTO-253
Therapeutic Area: Oncology Product Name: APTO-253
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
In earlier preclinical studies, HM43239 demonstrated potent in vitro and in vivo activity against FLT3 ITD mutated as well as resistance-conferring D835 and gatekeeper (F691) TKD mutated AML.
Lead Product(s): Tuspetinib
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Under the terms of the agreement, Hanmi has granted Aptose exclusive worldwide rights to HM43239 for all indications. HM43239 is a well-tolerated, once-daily oral agent with validated anti-leukemic activity in a highly challenging and heterogeneous malignancy like AML.
Lead Product(s): Tuspetinib
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Hanmi Pharmaceutical
Deal Size: $420.0 million Upfront Cash: $12.5 million
Deal Type: Licensing Agreement November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
